Mirikizumab for older adults with Crohn's or colitis
Treatments studied
Part of Digestive system clinical trials.
This trial tests a medication called Mirikizumab for adults over 60 with moderate to severe Crohn's disease or ulcerative colitis. It aims to see if the drug is safe and effective for older adults with these conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 60 years or older.
- You must have moderate to severe Crohn's disease or ulcerative colitis.
- You cannot have had major bowel surgery in the past 3 months.
- You cannot have an active infection requiring treatment right now.
- You cannot have had cancer (except some skin cancers) in the last 5 years.
- You cannot have unstable heart disease or uncontrolled high blood pressure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called mirikizumab for people with ulcerative colitis or Crohn's disease who have not responded well to other treatments. It aims to see if mirikizumab can help control symptoms and improve quality of life.
This study checks whether continuing mirikizumab (a medicine that calms gut inflammation) helps children with ulcerative colitis or Crohn’s disease after prior study treatment. It aims to see if staying on the medicine is beneficial and safe over time.
This trial tests if mirikizumab can reduce deep inflammation in the intestine walls in people with active Crohn's disease. It may help heal damage that shows up on an MRI scan.
This study tests mirikizumab to reduce inflammation and symptoms in children with Crohn’s disease that is currently active. It may help if your Crohn’s has not improved enough (or stopped working) with at least one other Crohn’s medicine.
This trial tests if starting with the stronger drug mirikizumab (top-down therapy) works better than the usual treatment with azathioprine for people newly diagnosed with moderate-to-severe ulcerative colitis. It aims to see which approach controls inflammation and improves symptoms faster.
This study tests a combination of a drug called mirikizumab and a surgical procedure (curettage and closure) for people with Crohn's disease who have an active perianal fistula. The goal is to see if this treatment helps heal the fistula better than standard care.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.